VLE Therapeutics

What VLE Therapeutics does

VLE Therapeutics is a Dublin, Ireland-based GMP contract development and manufacturing organization (CDMO) focused exclusively on advanced therapy medicinal products, including gene therapies, oncolytic viral vectors, vaccines, mRNA, and monoclonal antibodies. The company was established in 2022 as the dedicated GMP manufacturing arm of APC (Advanced Process Company), a process development firm founded in 2011 by Mark Barrett and Brian Glennon. VLE operates a 500 m² flexible GMP manufacturing facility co-located approximately five feet from APC's process development laboratories, a design choice that the company presents as enabling compressed CMC-to-GMP timelines.

VLE's technology stack centers on the iACHIEVE digital platform, which supports over 60 CMC-to-GMP programs and is paired with iTRANSFER, a knowledge management system designed to embed process knowledge across teams. Process capability includes 500L microcarrier scale bioreactors, AMBR 250 automated systems, self-optimizing bioreactors capable of measuring up to 30 metabolites every 4–6 seconds under a model predictive control architecture, CFD-based virtual mixing experiments, and rapid endotoxin testing (15–40 minutes, up to 5 samples). The facility was built in seven months, an indicator of execution speed relative to typical GMP build timelines. The company reports 200+ scientists across APC and VLE with 60% PhD-qualified staff, 22 nationalities, and 200+ years of combined GMP experience.

The business model is project-based GMP CDMO revenue, supplemented by QP certification, regulatory affairs, and supplier auditing services. VLE serves 100+ clients spanning early-stage biotech and large-cap pharma, with 80% of revenue described as export-driven. Reported customers include Bavarian Nordic for an RSV vaccine program. The company has raised no external funding, is fully bootstrapped, and operates from the parent APC's €75M infrastructure footprint, with an additional €100M Medicine Accelerator campus expansion announced that is expected to add 300 jobs.

Name

VLE Therapeutics

Legal name

VLE Ltd

Website

https://vletherapeutics.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

VLE Therapeutics is a Dublin-based GMP CDMO and the manufacturing arm of APC, providing process development through commercial GMP manufacturing for gene therapies, oncolytic viral vectors, vaccines, mRNA, and monoclonal antibodies to 100+ advanced therapy developers globally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO / GMP Manufacturing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• GMP manufacturing services
• Biopharmaceutical CDMO
• Cell and gene therapy
• Clinical manufacturing
• Process development

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. GMP Clinical Manufacturing Services: Fee-for-service GMP manufacturing contracts for clinical trials across modalities including gene therapies, oncolytic vectors, vaccines, mRNA, and monoclonal antibodies. Revenue is project-based, earned as manufacturing programs progress through clinical phases from Phase 1 through commercial launch. Not a capacity rental model — value is in accelerating client timelines and reducing cost-per-dose.
2. Pre-GMP Manufacturing Services: At-scale manufacturing services ahead of GMP including plasmid DNA production, toxicology batches, reference standard generation, at-scale process optimization runs, and material generation for process development. Delivered in collaboration with APC.
3. GMP QC Analytical Services: In-house analytical and bio-analytical quality control services including raw material conformance, sample management, in-process testing, and rapid endotoxin testing. Revenue is bundled into client GMP programs or charged as standalone services.
4. QP & Regulatory Services: Qualified Person (QP) certification and regulatory strategy services supporting EU, UK, and worldwide product releases and CMC pathway milestones.
5. Supplier Auditing Services: End-to-end supplier qualification services for biopharmaceutical sector, from needs assessment and risk evaluation to audit execution and supplier qualification.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

VLE Therapeutics is a science-first GMP manufacturing CDMO for advanced therapies, combining process development with in-house GMP clinical manufacturing for gene therapies, oncolytic vectors, vaccines, mRNA, and monoclonal antibodies. It offers an integrated services portfolio spanning pre-GMP manufacturing, GMP clinical manufacturing, GMP QC analytical services, GMP supply chain services, QP and regulatory services, supplier auditing, and tech transfer and scale-up. The service is enabled by proprietary digital workflow platforms iACHIEVE and iTRANSFER to streamline the path from molecule to clinical supply.

Product overview

VLE Therapeutics offers a science-first GMP manufacturing platform for advanced therapies. The core offering consists of The Medicine Accelerator framework combining iACHIEVE (digital CMC workflow platform) and iTRANSFER (knowledge management framework) with comprehensive manufacturing services including Pre-GMP Manufacturing, GMP Clinical Manufacturing across modalities (oncolytic vectors, cell & gene therapies, mRNA, monoclonal antibodies), GMP QC Analytical Services with Rapid Endotoxin Testing, GMP Supply Chain Services, QP & Regulatory Services, and Supplier Auditing. VLE's manufacturing modalities span Gene Therapies, Oncolytic Vectors, Vaccines, and Immunotherapies. The platform is distinguished by its proximity to process development (5 feet from APC's pilot plant) and integration with APC's Microcarrier Process Development capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Pre-GMP Manufacturing Services Pre-GMP manufacturing services that support process development, scale-up, and engineering runs before formal GMP clinical supply, enabling clients to derisk programs before GMP commitment. Intended for pharma and biotech developers of advanced therapies.
• GMP Clinical Manufacturing Full GMP clinical manufacturing of advanced therapies including gene therapies, oncolytic vectors, vaccines, mRNA, and monoclonal antibodies for clinical supply. Offered to pharma and biotech developers across pre-clinical through clinical stages.
• GMP QC Analytical Services GMP quality control analytical services supporting release and stability testing for GMP clinical manufacturing, including rapid endotoxin testing that releases materials in days. For pharma and biotech clients with advanced therapy programs.
• GMP Supply Chain Services GMP supply chain services supporting raw materials, consumables, and supplier management for advanced therapy clients. Used by pharma and biotech developers that need GMP-grade supply chain orchestration in parallel with manufacturing.
• QP and Regulatory Services Qualified Person (QP) and regulatory services supporting GMP clinical batch certification and regulatory submissions for advanced therapy programs. For pharma and biotech developers needing EU/UK QP release and CMC regulatory support.
• Supplier Auditing Services Supplier auditing services for GMP-grade raw materials and consumables used in advanced therapy manufacturing. For pharma and biotech clients that need third-party supplier qualification support.
• Tech Transfer and Scale-Up Services Technology transfer and scale-up services moving client processes from APC process development into GMP manufacturing, leveraging the iTRANSFER knowledge management framework to capture and transfer process knowledge, reports, and risk assessments. For pharma and biotech developers transferring advanced therapy processes.
• Microcarrier Process Development Microcarrier process development for adherent cell culture, scalable to 500L, supporting GMP clinical manufacturing of vaccines, gene therapies, and other advanced modalities. Cited use case includes process development for Bavarian Nordic.

Quantifiable outcome

• Reduced cost-per-dose to a fraction of original price for a client therapeutic (client example cited: from tens of millions per dose to a fraction of that cost)
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Two partnerships are on record, tiered core.

• APC (Advanced Process Consultants)coreStrategic or Co-development Partner · 1 January 2011APC is the sister company of VLE and the origin of the Medicine Accelerator model. Founded in 2011, APC provides world-class process development including self-optimizing bioreactors, microcarrier process development, computational fluid dynamics, and digital CMC platform iACHIEVE. VLE extends APC's process development capabilities into GMP clinical manufacturing, creating a seamless CMC-to-GMP pathway under one roof at Cherrywood Business Park.
• Bavarian NordiccoreStrategic or Co-development PartnerBavarian Nordic partnered with APC for the development of a novel, broad spectrum RSV vaccine candidate using APC's microcarrier-based process development in single-use bioreactors at up to 500L scale. This partnership demonstrates APC and VLE's ability to deliver clinically relevant manufacturing strategies for advanced vaccine candidates.

Scale indicators23 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Aldevron (Danaher): CDMO specializing in plasmid DNA, mRNA, and viral vector services that feed gene therapy and vaccine manufacturing pipelines. Highly comparable on the upstream nucleic acid / viral vector manufacturing side that VLE also serves.
• AGC Biologics: Global CDMO with dedicated cell and gene therapy services including viral vector manufacturing. Offers similar GMP clinical manufacturing services to biotech clients developing advanced therapies.
• Oxford BioMedica: UK-based CDMO specializing in lentiviral vector development and manufacturing for gene and cell therapies. Closely comparable to VLE in modality focus, science-led positioning, and target customer base of advanced therapy developers.

Broad incumbents

• Charles River Laboratories: Major CRO/CDMO with cell and gene therapy manufacturing services (including Cobra Biologics). A larger incumbent competing in advanced therapy manufacturing and related CDMO services.
• Thermo Fisher Scientific (Patheon): Global life sciences giant offering pharmaceutical development and manufacturing services through Patheon, including viral vector and cell therapy capabilities. A broad incumbent with overlapping service offerings.
• Lonza: One of the largest global CDMOs offering mammalian and microbial biologics manufacturing plus cell and gene therapy services. Directly comparable on the gene therapy/biologics CDMO axis but operates at a vastly larger and more diversified scale than VLE.
• Catalent (Novo Holdings): Global CDMO with established cell and gene therapy services and viral vector manufacturing capabilities across multiple sites. A broad incumbent that competes with VLE in advanced therapy GMP manufacturing, though its scale and breadth differ substantially from VLE's science-first niche model.
• WuXi Advanced Therapies (WuXi AppTec): Global CDMO with significant cell and gene therapy manufacturing capabilities. Competes with VLE for advanced therapy clients, though at much greater scale and with broader service portfolio.

Others

• APC (Advanced Process Company): VLE's sister company and referral source. APC provides process development expertise (microcarrier, bioreactor, CFD, iACHIEVE) that VLE extends into GMP manufacturing. Strategic ecosystem partner rather than a direct competitor.

Emerging players

• Resilience: Newer well-capitalized CDMO focused on advanced biologics and gene therapy manufacturing. Comparable emerging player targeting similar advanced therapy client segment, though with substantially different funding profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCbYPTPRmfu5RMTq7f9BhMyw
• LinkedInlinkedin.com/company/vle-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VLE Therapeutics